Workflow
普利制药(300630) - 2023 Q1 - 季度财报
HNPOLYHNPOLY(SZ:300630)2023-04-24 16:00

Financial Performance - The company's revenue for Q1 2023 was CNY 373,166,292.20, representing a 1.42% increase compared to CNY 367,925,505.63 in the same period last year[13] - Net profit attributable to shareholders decreased by 14.43% to CNY 138,433,086.41 from CNY 161,777,968.14 year-on-year[13] - The total comprehensive income for the first quarter of 2023 was approximately CNY 138.43 million, a decrease from CNY 161.78 million in the same period last year, representing a decline of about 14.4%[43] - Basic and diluted earnings per share for the first quarter were CNY 0.32, down from CNY 0.37 in the previous year, indicating a decrease of approximately 13.5%[43] Cash Flow - The net cash flow from operating activities increased by 29.21% to CNY 28,782,865.71 compared to CNY 22,275,788.10 in the previous year[13] - Cash inflow from operating activities totaled CNY 446.38 million, an increase of 24.8% compared to CNY 357.66 million in the same period last year[43] - Cash outflow from operating activities was CNY 417.60 million, up from CNY 335.38 million, resulting in a net cash flow from operating activities of CNY 28.78 million, an increase of 29.5% year-over-year[43] - The company's cash flow statement indicates a stable cash position, with no significant changes reported in cash flow from operating activities[26] - The ending balance of cash and cash equivalents was CNY 530.38 million, compared to CNY 470.60 million at the end of the previous year, reflecting a decrease in cash reserves[45] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 6,199,028,028.60, a 25.50% increase from CNY 4,939,389,761.87 at the end of the previous year[13] - The company's cash and cash equivalents decreased to CNY 558,387,952.23 from CNY 777,248,693.86[19] - Accounts receivable increased to CNY 1,014,589,461.88 from CNY 924,070,859.41, indicating a growth of approximately 9.7%[19] - Current liabilities decreased to CNY 1,248,308,071.79 from CNY 1,484,098,044.10, a reduction of approximately 15.9%[22] - Long-term borrowings increased to CNY 999,238,137.82 from CNY 689,214,991.96, representing a growth of about 45%[22] - The total liabilities rose to ¥3,258,533,476.71 from ¥3,156,510,196.83, an increase of approximately 3.23%[36] Investment and Expenses - The company reported a significant increase in investment income, rising by 1646.10% to CNY 2,463,766.47 from CNY 141,101.23 in the previous year[16] - Research and development expenses amounted to ¥61,517,923.07, compared to ¥56,659,055.19 in the previous period, indicating an increase of about 8.25%[24] - Total operating costs increased to ¥243,515,781.30 from ¥212,061,775.12, marking a rise of about 14.85%[24] - Tax expenses decreased to ¥1,076,155.70 from ¥6,010,278.61, a reduction of approximately 82.06%[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,586[16] - The company has a total of 113,674,906 shares, with 25% of these shares subject to a lock-up period[18] - The total equity attributable to shareholders increased to ¥2,940,494,551.89 from ¥2,802,510,631.14, reflecting a growth of about 4.93%[36]